ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 64 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 3.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $0 | -100.0% | 2,274 | -38.0% | 0.00% | – |
| Q4 2022 | $1 | -100.0% | 3,667 | +273.8% | 0.00% | – |
| Q1 2022 | $2,000 | -94.1% | 981 | -90.4% | 0.00% | – |
| Q2 2020 | $34,000 | +240.0% | 10,210 | +413.3% | 0.00% | – |
| Q1 2019 | $10,000 | 0.0% | 1,989 | -43.5% | 0.00% | – |
| Q4 2018 | $10,000 | -78.3% | 3,519 | -38.7% | 0.00% | – |
| Q3 2018 | $46,000 | +70.4% | 5,742 | +78.2% | 0.00% | -100.0% |
| Q1 2018 | $27,000 | +285.7% | 3,222 | +471.3% | 0.00% | – |
| Q4 2017 | $7,000 | -72.0% | 564 | -81.4% | 0.00% | -100.0% |
| Q3 2017 | $25,000 | -86.8% | 3,029 | -72.9% | 0.00% | -87.5% |
| Q2 2017 | $189,000 | -59.5% | 11,196 | -51.9% | 0.01% | -60.0% |
| Q1 2017 | $467,000 | +436.8% | 23,260 | +312.6% | 0.02% | +300.0% |
| Q4 2016 | $87,000 | – | 5,638 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |